Lyell Immunopharma (NASDAQ:LYEL) Stock

LYELL IMMUNOPHARMA INC

Lyell Immunopharma

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Truist Securities analyst Michael Ciarmoli maintains Heico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) with a Buy and raises the price target from $323 to $352.

News

Price Target

Analyst Ratings

Truist Securities Maintains Buy on Heico, Raises Price Target to $352

Truist Securities analyst Michael Ciarmoli maintains Ducommun (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>) with a Buy and raises the price target from $87 to $95.

Truist Securities Maintains Buy on Ducommun, Raises Price Target to $95

WIIM

VEON

VEON shares are trading higher after the company and Cohen Circle Acquisition executed non-redemption agreements.

Truist Securities analyst Michael Ciarmoli maintains AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) with a Buy and raises the price target from $78 to $81.

Truist Securities Maintains Buy on AAR, Raises Price Target to $81

Wells Fargo analyst Michael Brown maintains T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Equal-Weight and raises the price target from $98 to $108.

TROW

Wells Fargo Maintains Equal-Weight on T. Rowe Price Group, Raises Price Target to $108

Wells Fargo analyst Michael Brown maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Overweight and raises the price target from $140 to $156.

Wells Fargo Maintains Overweight on KKR, Raises Price Target to $156

Wells Fargo analyst Michael Brown maintains Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) with a Equal-Weight and raises the price target from $37 to $44.

Janus Henderson Group plc Ordinary Shares

Wells Fargo Maintains Equal-Weight on Janus Henderson Group, Raises Price Target to $44

Truist Securities analyst Jennifer Demba maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Hold and raises the price target from $52 to $57.

ZION

Truist Securities Maintains Hold on Zions Bancorp, Raises Price Target to $57

Wells Fargo analyst Michael Brown maintains Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) with a Equal-Weight and raises the price target from $161 to $162.

HLNE

Wells Fargo Maintains Equal-Weight on Hamilton Lane, Raises Price Target to $162

Truist Securities analyst David Smith maintains Webster Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) with a Buy and raises the price target from $61 to $67.

Truist Securities Maintains Buy on Webster Financial, Raises Price Target to $67

Wells Fargo analyst Michael Brown maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Equal-Weight and raises the price target from $21.5 to $26.

Wells Fargo Maintains Equal-Weight on Franklin Resources, Raises Price Target to $26

Most Americans think they're playing it smart with credit cards—earning points here, dodging interest there. But when Tucker Carlson asked financial guru Dave Ramsey a simple question—"What's wrong with having a credit card if you pay the balance every month?"—he didn't expect the answer to unravel a myth baked into American consumer habits.
"Most people don't," Ramsey replied. "That's the great lie." He added, "Everybody talks about this theoretical discipline that they just freaking don't have."
It wasn't just a hot take—it was backed by data. "78% roll the balance over month to month," Ramsey said. "Just like 97% of the people don't pay a 30-year mortgage like a 15."
Don't Miss:
<ul class="wp-block-list">
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $10.</a></li>
<li>$100k+ in investable assets? <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes</a> – no cost, no obligation.</li>
</ul>
Carlson, who invited Ramsey onto <a href="https://youtu.be/KwZG7QlfVe8?si=A-nxr_wTtHqgNEd3">"The Tucker Carlson Show" last October</a>, seemed genuinely surprised. But Ramsey wasn't finished. He pointed to the emotional grip credit cards have on Americans. "People have physical reactions when they cut up their credit cards. I mean they're—they're crying, they're shaking."
Ramsey, who built a financial empire around the idea of living debt-free, doesn't own a single credit card. "I don't have credit cards. I haven't, you know, in 30-something years," he said. "I have debit cards on my business and debit cards on my personal account, and I use it like most people use a credit card."
He argued debit cards do everything credit cards do—just without the risk. "If you're going to <a href="https://www.benzinga.com/personal-finance/management/25/06/45779656/a-couple-followed-dave-ramsey-and-got-out-of-debt-then-they-took-a-hard-turn-and-ended-up-46000-in-the-red-on-13-credit-cards">pay your credit card off</a> every month and you're really going to do that, then a debit card will work… it's the exact same freaking thing."
But for most people, it doesn't play out that way. "The average American right now is $37,000 in credit card debt," Ramsey said. "They charge 18 to 28%… so you run that out times 300 million and you've got some money coming into good old Chase."
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
When Carlson asked why credit card companies seem untouchable—never facing backlash the way banks, corporations, or politicians do—Ramsey pointed to marketing. "We're taught again with the most repetitive sophisticated marketing over the longest period of time in human history… we've been taught don't leave home without it."
He called the messaging so effective it's become something of a religion. "It's an altar that we worship at," Ramsey said. "And it's not."
He even took aim at people who claim to be making money with cards. "People with a master's degree in finance: ‘I got 1% back on my Discover card.' So you're going to run 100 grand through your Discover card to get $1,000 back. On what planet does that build wealth?"
Carlson laughed but stayed focused. "So you're just saying, your argument is they're just too dangerous."
"It's not even that it's that dangerous. If you are paying it off every month, it's not going to bankrupt you," Ramsey said. But even then, he warned, the psychological impact of using plastic changes how people spend.
"When you swipe plastic, you spend 12 to 18% more than if you lay down actual cash," he said, <a href="https://mitsloan.mit.edu/press/mit-sloan-study-shows-credit-cards-act-to-step-gas-to-increase-spending">citing an MIT study</a>. "Because cash, when you see Benjamin looking at you, activates the pain center of the brain."
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
With cards—or worse, Apple Pay—there's no mental friction. "You just moved your phone around like you just returned an email or a text and now you're walking out of Home Depot with another tool."
Even the way stores hand back your card tricks the brain. "When you hand someone a piece of plastic at the store, they hand you the groceries or the shirt back with the plastic," he said. "When you hand them money, they just hand you the shirt."
Ramsey and his wife still pay for groceries in cash. "Sharon still carries an envelope with cash in it in her purse for—it says groceries on it," he said.
Despite the <a href="https://www.benzinga.com/25/05/45297103/a-dave-ramsey-fan-explains-how-they-feel-free-after-cutting-every-credit-card-im-tired-of-managing-payments-every-month">cultural dependence on cards</a>, Ramsey says it doesn't have to be that way. Debit cards work for car rentals and hotel bookings, and fraud protection exists for both. "You actually have to have money in your freaking account in order to spend it," he said.
To him, the risks, the habits, and the industry profits all add up to one conclusion: "There's no point."
Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
Image: Shutterstock

Personal Finance

Tucker Carlson Asks Dave Ramsey Why Credit Cards Are a Problem If You Pay Them Off — Ramsey Says, 'That's the Great Lie… Most People Don't'

Truist Securities analyst Brandon King maintains Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Buy and raises the price target from $92 to $96.

Truist Securities Maintains Buy on Western Alliance, Raises Price Target to $96

Wells Fargo analyst Michael Brown maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Underweight and raises the price target from $55 to $57.

Wells Fargo Maintains Underweight on Brookfield Asset Mgmt, Raises Price Target to $57

Truist Securities analyst Brian Foran maintains UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Buy and raises the price target from $120 to $128.

UMBF

Truist Securities Maintains Buy on UMB Financial, Raises Price Target to $128

GLBKV

Trading Halt: Halt status updated at 9:40:00 AM ET: Quotation Resumption: New Issue Available

GLBAV

Trading Halt: Halt status updated at 9:40:02 AM ET: Quotation Resumption: New Issue Available

Wells Fargo analyst Michael Brown maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Equal-Weight and raises the price target from $153 to $167.

Wells Fargo Maintains Equal-Weight on Blackstone, Raises Price Target to $167

Wells Fargo analyst Michael Brown maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Overweight and raises the price target from $189 to $202.

ARES

Wells Fargo Maintains Overweight on Ares Management, Raises Price Target to $202

Wells Fargo analyst Michael Brown maintains Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and raises the price target from $160 to $173.

Wells Fargo Maintains Overweight on Apollo Asset Management, Raises Price Target to $173

Health Care

Press Releases

General

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Earnings

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Comments

Lyell Immunopharma

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL